Brief: Infinity Pharmaceuticals Reports Q1 Loss Per Share Of $0.19
11/05/2020 12:38
May 11 (Reuters) - Infinity Pharmaceuticals Inc INFI.O :
* Q1 LOSS PER SHARE $0.19
* Q1 EARNINGS PER SHARE ESTIMATE $-0.13 -- REFINITIV IBES
DATA
* INFINITY VOLUNTARILY PAUSING ENROLLMENT ON MARIO-275 TO
EVALUATE
RISK/BENEFIT FOR PATIENTS
* FAST TRACK DESIGNATION GRANTED FOR IPI-549 PLUS OPDIVO(®)
IN
PATIENTS WITH ADVANCED UROTHELIAL CANCER
* COMPLETION OF ENROLLMENT FOR MARIO-275 AND MARIO-3 DELAYED
* $20M ASSET BACKED FINANCING WITH BVF IN JANUARY; CASH
RUNWAY
INTO H2 2021
* EXPECTS NET LOSS FOR 2020 TO RANGE FROM $40 MILLION TO $50
MILLION.
Source text for Eikon: ID:nBw86hdfda
Further company coverage: INFI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Infinity Pharmaceuticals
See all newsBrief: Infinity Pharmaceuticals Filed Voluntary Petition For Relief Under Provisions Of Chapter 11
Brief: Infinity Pharmaceuticals Inc Received Determination Letter From Nasdaq On September 12
Brief: Infinity Pharma Says On Sept 5, 2023, Co Received Letter From Nasdaq Notifying That Listing Of Common Stock Was Not In Compliance With Nasdaq Listing Rule
Brief: Infinity Pharmaceuticals Approved Plan To Reduce Co's Overall Headcount By 21 Positions
U.S. STOCKS ON THE MOVE-General Motors, Estee Lauder, IMAX